Literature DB >> 6866591

Methylphenidate hydrochloride given with or before breakfast: I. Behavioral, cognitive, and electrophysiologic effects.

J M Swanson, C A Sandman, C Deutsch, M Baren.   

Abstract

Methylphenidate HCl (Ritalin) is usually given for the treatment of hyperactivity or attention deficit disorder (ADD) at 30 minutes to one hour before meals. This schedule is based on the assumption that, when taken with meals, its absorption or metabolism is altered. However, no behavioral or pharmacologic data exist to support this recommendation. Eleven patients with attention deficit disorder were tested to evaluate this hypothesis using a double-blind crossover design (methylphenidate with or before breakfast) with a placebo control condition. Parents' ratings, performance on a paired-associate learning test, and cortical auditory-evoked potentials were measured. All of these measurements showed clear differences between the placebo condition and conditions when medication was given. However, none of the measurements showed a significant difference between the conditions when methylphenidate was given with breakfast and the condition when methylphenidate was given 30 minutes before breakfast.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6866591

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  27 in total

1.  Asperger syndrome and nonverbal learning difficulties in adult males: self- and parent-reported autism, attention and executive problems.

Authors:  Bibbi Hagberg; Eva Billstedt; Agneta Nydén; Christopher Gillberg
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-11-16       Impact factor: 4.785

Review 2.  Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.

Authors:  Morris Zwi; Hannah Jones; Camilla Thorgaard; Ann York; Jane A Dennis
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

3.  Psychostimulant effects on academic and behavioral measures for ADHD junior high school students in a lecture format classroom.

Authors:  S W Evans; W E Pelham
Journal:  J Abnorm Child Psychol       Date:  1991-10

Review 4.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.

Authors:  Luigi Mazzone; Laura Reale; Valeria Mannino; Mariadonatella Cocuzza; Benedetto Vitiello
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

Review 6.  Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.

Authors:  Vanessa R Anderson; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Methylphenidate in hyperactive children: differential effects of dose on academic, learning, and social behavior.

Authors:  M D Rapport; G Stoner; G J DuPaul; B K Birmingham; S Tucker
Journal:  J Abnorm Child Psychol       Date:  1985-06

8.  Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale - parent form.

Authors:  Susan Shur-Fen Gau; Chi-Yung Shang; Shih-Kai Liu; Chien-Ho Lin; James M Swanson; Yu-Chih Liu; Chang-Ling Tu
Journal:  Int J Methods Psychiatr Res       Date:  2008       Impact factor: 4.035

9.  Inattentive and hyperactive preschool-age boys have lower sympathetic and higher parasympathetic activity.

Authors:  Tzong-Shi Wang; Wei-Lieh Huang; Terry B J Kuo; Guo-She Lee; Cheryl C H Yang
Journal:  J Physiol Sci       Date:  2012-10-18       Impact factor: 2.781

Review 10.  Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

Authors:  Johnny Graham; David Coghill
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.